Insider Selling: Tandem Diabetes Care COO Sells 2,000 Shares of Stock (TNDM)
Tandem Diabetes Care (NASDAQ:TNDM) COO John F. Sheridan sold 2,000 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $13.99, for a total value of $27,980.00. Following the completion of the sale, the chief operating officer now directly owns 1,198 shares in the company, valued at approximately $16,760. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on TNDM shares. Analysts at Bank of America upgraded shares of Tandem Diabetes Care from a “neutral” rating to a “buy” rating in a research note on Friday, August 1st. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Tandem Diabetes Care in a research note on Friday, August 1st. They now have a $25.00 price target on the stock. Finally, analysts at William Blair initiated coverage on shares of Tandem Diabetes Care in a research note on Tuesday, July 15th. They set an “outperform” rating and a $2.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $20.75.
Shares of Tandem Diabetes Care (NASDAQ:TNDM) traded down 2.42% during mid-day trading on Wednesday, hitting $13.73. The stock had a trading volume of 70,174 shares. Tandem Diabetes Care has a 52 week low of $1.791 and a 52 week high of $30.25. The stock has a 50-day moving average of $13.85 and a 200-day moving average of $17.79. The company’s market cap is $322.1 million.
Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings data on Thursday, July 31st. The company reported ($0.83) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.91) by $0.08. The company had revenue of $10.26 million for the quarter, compared to the consensus estimate of $10.36 million. Tandem Diabetes Care’s revenue was up 85.5% compared to the same quarter last year. On average, analysts predict that Tandem Diabetes Care will post $-3.39 earnings per share for the current fiscal year.
Tandem Diabetes Care, Inc is a medical device company with an approach to design, develop and commercialize products for people with insulin-dependent diabetes.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.